Home > Compound List > Product Information
FIPI hydrochloride hydrate_Molecular_structure_CAS_)
Click picture or here to close

FIPI hydrochloride hydrate

Catalog No. F5807 Name Sigma Aldrich
CAS Number Website http://www.sigmaaldrich.com
M. F. C23H27ClFN5O3 Telephone 1-800-521-8956
M. W. 475.9435832 Fax
Purity ≥98% (HPLC) Email
Storage Chembase ID: 154463

SYNONYMS

IUPAC name
5-fluoro-N-{2-[4-(2-oxo-2,3-dihydro-1H-1,3-benzodiazol-1-yl)piperidin-1-yl]ethyl}-1H-indole-2-carboxamide hydrate hydrochloride
IUPAC Traditional name
5-fluoro-N-{2-[4-(2-oxo-3H-1,3-benzodiazol-1-yl)piperidin-1-yl]ethyl}-1H-indole-2-carboxamide hydrate hydrochloride
Synonyms
4-Fluoro-N-(2-(4-(5-fluoro-1H-indol-1-yl)piperidin-1-yl)ethyl)benzamide
5-Fluoro-2-indolyl des-chlorohalopemide hydrochloride hydrate

DATABASE IDS

MDL Number MFCD12912411

PROPERTIES

Empirical Formula (Hill Notation) C23H24FN5O2·HCl · xH2O
Purity ≥98% (HPLC)
Apperance off-white powder
Solubility DMSO: >20 mg/mL
GHS Pictograms GHS07
GHS Signal Word Warning
GHS Hazard statements H315-H319-H335
European Hazard Symbols Irritant Irritant (Xi)
MSDS Link Download
GHS Precautionary statements P261-P305 + P351 + P338
Risk Statements 36/37/38
Safety Statements 26
Storage Temperature 2-8°C
German water hazard class 3

DETAILS

Description (English)
Biochem/physiol Actions
FIPI is a potent Phospholipase D (PLD) inhibitor. The signaling enzyme Phospholipase D (PLD) and the lipid second messenger phosphatidic acid (PA) generated by PLD are implicated in many cell biological processes including Ras activation, cell spreading, stress fiber formation, chemotaxis, and membrane vesicle trafficking. FIPI is a potent in vivo inhibitor of both PLD1 and PLD2, setting the stage for a new era of exploration and validation of cell biological roles for mammalian PLD. It rapidly blocks in vivo PA production with sub-nM potency. FIPI inhibits PLD regulation of F-actin cytoskeleton reorganization, cell spreading, and chemotaxis, indicating potential utility for it as a therapeutic for autoimmunity and cancer metastasis. It does not affect PLD subcellular localization, PIP2 availability, the actin stress fiber network in resting CHO cells, or selected signaling events proximal to PLD activation.
FIPI is a potent phospholipase D (PLD) inhibitor effective at sub-nM levels. Phospholipase D (PLD) and the lipid second messenger phosphatidic acid (PA) generated by PLD are implicated in many cell biological processes including Ras activation, cell spreading, stress fiber formation, chemotaxis, and membrane vesicle trafficking. FIPI inhibits both PLD1 and PLD2, rapidly blocking in vivo PA production. FIPI inhibits PLD regulation of F-actin cytoskeleton reorganization, cell spreading, and chemotaxis, suggesting potential as a therapeutic for autoimmune diseases and cancer metastasis.
Description (简体中文)
Biochem/physiol Actions
FIPI is a potent Phospholipase D (PLD) inhibitor. The signaling enzyme Phospholipase D (PLD) and the lipid second messenger phosphatidic acid (PA) generated by PLD are implicated in many cell biological processes including Ras activation, cell spreading, stress fiber formation, chemotaxis, and membrane vesicle trafficking. FIPI is a potent in vivo inhibitor of both PLD1 and PLD2, setting the stage for a new era of exploration and validation of cell biological roles for mammalian PLD. It rapidly blocks in vivo PA production with sub-nM potency. FIPI inhibits PLD regulation of F-actin cytoskeleton reorganization, cell spreading, and chemotaxis, indicating potential utility for it as a therapeutic for autoimmunity and cancer metastasis. It does not affect PLD subcellular localization, PIP2 availability, the actin stress fiber network in resting CHO cells, or selected signaling events proximal to PLD activation.
FIPI is a potent phospholipase D (PLD) inhibitor effective at sub-nM levels. Phospholipase D (PLD) and the lipid second messenger phosphatidic acid (PA) generated by PLD are implicated in many cell biological processes including Ras activation, cell spreading, stress fiber formation, chemotaxis, and membrane vesicle trafficking. FIPI inhibits both PLD1 and PLD2, rapidly blocking in vivo PA production. FIPI inhibits PLD regulation of F-actin cytoskeleton reorganization, cell spreading, and chemotaxis, suggesting potential as a therapeutic for autoimmune diseases and cancer metastasis.

REFERENCES